Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$48.59M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| January 1, 2025 – December 31, 2025 | $71,610,000 | February 12, 2026 | 10-K ↗ |
| January 1, 2024 – December 31, 2024 | $64,251,000 | February 12, 2026 | 10-K ↗ |
| January 1, 2023 – December 31, 2023 | $50,143,000 | February 13, 2025 | 10-K ↗ |
| January 1, 2022 – December 31, 2022 | $34,421,000 | February 22, 2024 | 10-K ↗ |
| July 1, 2020 – June 30, 2021 | $29,232,000 | February 23, 2023 | 10-K ↗ |
| July 1, 2019 – June 30, 2020 | $14,263,000 | August 26, 2021 | 10-K ↗ |
| July 1, 2018 – June 30, 2019 | $5,474,000 | August 26, 2021 | 10-K ↗ |
| July 1, 2017 – June 30, 2018 | $929,000 | August 27, 2020 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:Revenues · Retrieved October 11, 2026
Response SHA-256: 49b6ed19f02b898849687084c1e3e18e128ba3153bd6915f427c3814d52c13f5
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.